Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that long-term use of finasteride does not affect bone mineral density in men with benign prostatic hyperplasia over a four-year period.

This study reported that derivatization with 5-butylpicolinic acid improved the sensitivity for detecting testosterone and DHT in saliva using LC-ESI-MS/MS, with minimal interference from the saliva matrix.

This study reported that the n-butanol fraction of Perilla frutescens extract, particularly rosmarinic acid, showed potential for hair regrowth and anti-androgenic activity in male mice, suggesting it as a possible treatment for androgenetic alopecia.

This review discusses idiopathic hirsutism and suggests that combination treatment, including androgen suppression and cosmetic methods, is most effective, but notes that its pathogenesis remains unclear.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

This review suggests that hair loss involves a complex interplay of androgen signaling with various regenerative and inflammatory pathways, challenging the view of dihydrotestosterone as the sole cause.

This narrative literature review by LUSTRAO examines the complex biological mechanisms influencing hair growth and loss, highlighting that androgen signalling, while significant, works within a network involving regenerative, inflammatory, and vascular processes, without establishing it as the sole explanation for conditions like androgenetic alopecia.

This study found that exosomes derived from hypoxia-conditioned mesenchymal stem cells modulated inflammatory biomarkers by decreasing CXCL12 and increasing IL-10 expression in a DHT-induced androgenic alopecia mouse model, indicating potential for treating hair loss through immunoregulation.

This review discusses the role of steroid 5 alpha reductase 2 in converting testosterone to DHT and its association with conditions like benign prostatic hyperplasia and prostate cancer; it reports no new results.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

The conclusion suggests a new treatment for infantile hemangiomas and a potential target for hair loss treatment.

This study found that Cacumen platycladi extract significantly promoted hair growth and reduced dihydrotestosterone levels by inhibiting 5α-reductase activity in an androgen-sensitive mouse model.

Botulinum toxin may help hair loss by increasing blood flow and reducing harmful factors.

In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.

Both drugs lower DHT levels, with GI198745 being more effective.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

This study found that finasteride significantly reduced hirsutism in women with idiopathic hirsutism or polycystic ovary syndrome over six months, suggesting its potential effectiveness for this condition.

In this study, finasteride treatment did not negatively impact bone development or density in male rats, suggesting that DHT deficiency is not harmful to the male rat skeleton.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This study found that coadministration of 5α-reductase inhibitors with oral testosterone in oil significantly increases serum testosterone levels in medically castrated men compared to testosterone alone, with food intake minimally affecting these levels.

Over 50% of women over 50 experience hair loss, with minoxidil being the only proven effective treatment.

This study concluded that finasteride treatment did not adversely affect bone development or density in male rats, suggesting selective DHT deficiency is not harmful to the skeleton.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

This chapter reviews recent advances in 5α-reductase inhibitors for treating disorders mediated by dihydrotestosterone and reports no new clinical findings.

This review discusses the role of androgens in male sexual differentiation and characteristics and reports no new clinical results; it emphasizes the androgen dependence of male pattern scalp hair loss.

This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.

This review outlines that minoxidil (topical and oral) and 5α-reductase inhibitors are the most effective treatments for androgenetic alopecia, with additional therapies like platelet-rich plasma and hair transplantation enhancing results, emphasizing the need for individualized, combination approaches.